Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAltimmune, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 5 | -$0.38 | -$0.30 | -$0.35 |
| Q2 2025 | 7 | -$0.39 | -$0.27 | -$0.34 |
| Q3 2025 | 6 | -$0.30 | -$0.24 | -$0.27 |
| Q4 2025 | 6 | -$0.30 | -$0.23 | -$0.25 |
| Q1 2026 | 5 | -$0.31 | -$0.22 | -$0.27 |
| Q2 2026 | 1 | -$0.29 | -$0.29 | -$0.29 |
| Q3 2026 | 1 | -$0.31 | -$0.31 | -$0.31 |
| Q4 2026 | 1 | -$0.35 | -$0.35 | -$0.35 |
| Q1 2027 | 1 | -$0.81 | -$0.81 | -$0.81 |
| Q2 2027 | 1 | -$0.34 | -$0.34 | -$0.34 |
| Q3 2027 | 1 | -$0.34 | -$0.34 | -$0.34 |
| Q4 2027 | 1 | -$0.34 | -$0.34 | -$0.34 |
Altimmune, Inc. Earnings Date And Information
Altimmune, Inc. last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.21 earnings per share for the quarter, topping analysts' consensus estimates of $-0.29 by $0.08. The company had revenue of 5.00 K for the quarter and had revenue of 20.00 K for the year. Altimmune, Inc. has generated $-1 earnings per share over the last year ($-1.34 diluted earnings per share) and currently has a price-to-earnings ratio of -5.98. Altimmune, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 11th, 2025 based on prior year's report dates.
Altimmune, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$0.29 | -$0.21 | 0.08 | $1.43 K | $5.00 K |
| 08/12/2025 | Q2 2025 | -$0.32 | -$0.27 | 0.05 | $1.43 K | $5.00 K |
| 05/13/2025 | Q1 2025 | -$0.35 | -$0.26 | 0.09 | N/A | $5.00 K |
| 02/27/2025 | Q4 2024 | -$0.34 | -$0.33 | 0.01 | N/A | $5.00 K |
| 11/12/2024 | Q3 2024 | -$0.36 | -$0.32 | 0.04 | $714 | $5.00 K |
| 08/08/2024 | Q2 2024 | -$0.34 | -$0.35 | -0.01 | $714 | $5.00 K |
| 05/09/2024 | Q1 2024 | -$0.36 | -$0.34 | 0.02 | N/A | $5.00 K |
| 03/27/2024 | Q4 2023 | -$0.35 | -$0.54 | -0.19 | N/A | $37.00 K |
| 11/07/2023 | Q3 2023 | -$0.40 | -$0.39 | 0.01 | $857 | $362.00 K |
| 08/10/2023 | Q2 2023 | -$0.44 | -$0.32 | 0.12 | $3.00 K | $6.00 K |
| 05/11/2023 | Q1 2023 | -$0.49 | -$0.37 | 0.12 | $37.14 K | $21.00 K |
| 02/28/2023 | Q4 2022 | -$0.52 | -$0.40 | 0.12 | $28.86 K | $-110,000 |
| 11/10/2022 | Q3 2022 | -$0.49 | -$0.48 | 0.01 | $867.83 K | $2.00 K |
| 08/11/2022 | Q2 2022 | -$0.45 | -$0.42 | 0.03 | $871.50 K | $8.00 K |
| 05/12/2022 | Q1 2022 | -$0.57 | -$0.44 | 0.13 | $1.03 M | $32.00 K |
| 03/15/2022 | Q4 2021 | -$0.64 | -$0.57 | 0.07 | $90.33 K | $3.28 M |
| 11/09/2021 | Q3 2021 | -$0.36 | -$0.81 | -0.45 | $70.67 K | $158.00 K |
| 08/10/2021 | Q2 2021 | -$0.44 | -$0.60 | -0.16 | $1.89 M | $137.00 K |
| 05/17/2021 | Q1 2021 | -$0.39 | -$0.38 | 0.01 | $2.07 M | $838.00 K |
| 02/25/2021 | Q4 2020 | -$0.84 | -$0.27 | 0.57 | $1.78 M | $2.31 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Altimmune, Inc. Earnings: FAQ's
Altimmune, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 11th, 2025 based offlast year's report dates.
In the previous quarter, Altimmune, Inc. (:ALT) reported $-0.21 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.29 by $0.08.
The conference call for Altimmune, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Altimmune, Inc.'s latest earnings report can be read online.
Altimmune, Inc. (:ALT) has a recorded annual revenue of $20.00 K.
Altimmune, Inc. (:ALT) has a recorded net income of $-95,059,000.Altimmune, Inc. has generated $-1.34 earnings per share over the last four quarters.
Altimmune, Inc. (:ALT) has a price-to-earnings ratio of -5.98 and price/earnings-to-growth ratio is -0.64.